GlassScriptPhysician profile
Janelle S Manton
NPI 1841267986
$6,534.88
in general payments reported to CMS, 2019-2025
30 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $174 · 2021: $388 · 2022: $865 · 2023: $1,453 · 2024: $1,330 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,675.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $614.06 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $333.22 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $316.22 | 2019-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $300.78 | 2022-2024 | Vtama |
| Pfizer INC. | $271.03 | 2020-2025 | |
| Ucb, INC. | $221.08 | 2019-2024 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $216.74 | 2019-2024 | Dupixent |
| Sun Pharmaceutical Industries INC. | $206.19 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $200.83 | 2019-2025 | |
| Incyte Corporation | $151.51 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $148.32 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Biotech, INC. | $133.00 | 2022-2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $119.82 | 2019-2020 | |
| Botanix Sb INC | $96.80 | 2025 | Sofdra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $70.99 | 2021-2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.63 | 2024-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $63.52 | 2019 | |
| Almirall LLC | $60.38 | 2019-2020 | |
| Genzyme Corporation | $52.35 | 2019-2023 | |
| Merz North America, INC. | $41.26 | 2024 | |
| Epi Health, LLC | $30.49 | 2022 | |
| Lnhc, INC | $20.92 | 2025 | Zelsuvmi |
| Organon LLC | $20.64 | 2025 | Vtama |
| Genentech USA, INC. | $18.74 | 2019 | |
| Dermira, INC. | $18.28 | 2019 | |
| Biofrontera INC. | $17.55 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.63 | 2022 | |
| Arcutis Biotherapeutics, INC. | $16.17 | 2023 | |
| Merck Sharp & Dohme LLC | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janelle Manton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.